Product Images Atorvastatin Calcium

This is a medication bottle label for Atorvastatin Calcium tablets manufactured by Mylan Pharmaceuticals. The tablets are film-coated and each contains 10 mg of atorvastatin. The label provides dosage instructions, storage instructions and company details. It also includes a code for variable data coding that includes LOT and EXP information.*

This is a medication label for Atorvastatin Calcium Tablets, USP, manufactured by Mylan Pharmaceuticals Inc. Each tablet contains an amount equivalent to 20 mg of atorvastatin. The usual dosage information is available with the accompanying prescribing information. The medication should be kept out of reach of children and stored at 20°C to 25°C. The tablets should be dispensed in a tightly closed, light-resistant container with a child-resistant closure. The label also includes various codes and printed information for data tracking purposes.*

Each film-coated tablet contains 40 mg of atorvastatin calcium, USP. The NDC number for this medication is 0378-3952-77. The package contains 90 tablets which should be stored at a temperature between 20°C to 25°C. It is important to keep the container tightly closed and use a child-resistant closure. The medication should be stored in a safe place where children can't reach. The manufacturing company is Mylan Pharmaceuticals Inc. The label includes space for variable data coding and information such as LOT and EXP. This product is made in India.*

This is a medication containing 80 mg of atorvastatin calcium, USP. It should be stored between 20°C to 25°C and kept out of reach of children. For dosage information, see the accompanying prescribing information. It is manufactured by Mylan Pharmaceuticals Inc. and dispensed in a tight, light-resistant container with a child-resistant closure. The lot number is 1234567, and it is suggested to check the expiration date printed as "EXP MMM.YYYY".*

The given text presents a chart showing the cumulative hazard in percentage along with a statistical analysis. The chart represents data for time to the first primary endpoint through four years of follow-up. The Hazard Ratio (HR) with a confidence interval and p-value is also provided.*

The text is a statistical analysis of the effectiveness of Atorvastatin at different doses in reducing the risk of major cardiovascular endpoint over a period of time. Specifically, the text lists the percentage of subjects that experienced the event, the hazard ratio, and the probability value for each Atorvastatin dose. It also shows a graph with four time intervals (in years) on the x-axis and the probability of experiencing the endpoint on the y-axis.*